Bionano Genomics stock rises after study shows optical genome mapping better detects cancer

Bionano Genomics Inc BNGO shares are trading higher Wednesday after the company highlighted a study showing that optical genome mapping better detected structural variations in liver cancer.

In the study, optical genome mapping OGM helped unravel replication stress-induced events that may cause or contribute to genomic instability in cancer cells, possibly leading to the activation of oncogenes and disruption of tumor suppressors.

The study compared OGM to Whole Genome Sequience WGS and found that WGS detected only 63% of the variations that OGM detected.

Cancer is often thought of as a disease of structural variation, and this study shows how OGM can help unravel the complex mechanisms involved in oncogenesis. Erik Holmlin, president and CEO of Bionano Genomics said that OGM can be more sensitive for detecting large structural variations than WGS and shows how complementary the two methods are.

Bionano Genomics is a provider of genome analysis solutions that can be used to reveal answers to challenging questions in biology and medicine.

See also: US Stocks Could Pause For Breather After 2 Session Rally As Futures Slump; Twitter, Tesla, Ford On Investor Radar

Bionano Genomics has a 52 week high of $4.35 and a 52 week low of $1.16, according to BNGO Price Action.

The stock rose by 13.3% on Tuesday and was up 11.8% Wednesday morning, according to Benzinga Pro.